Abstract | BACKGROUND: METHODS: PubMed, Embase, the Cochrane Library, Scopus, and the ClinicalTrials.gov registry were searched for studies published up to July 2015. Individual effect sizes were standardized, and a meta-analysis was performed to calculate a pooled effect size by using random effects models. Pain was assessed using a visual analog scale at 1, 2, 12, and 24 h postoperatively. The secondary outcomes included complications and analgesic consumption. RESULTS: We reviewed 13 trials with 1150 patients. We found no difference in postoperative pain reduction at 1, 12, and 24 h after breast cancer surgery between the experimental and control groups. The severity of pain was significantly reduced in the experimental group (weighted mean difference -0.19; 95% confidence interval: -0.39-0.00) at 2 h postoperatively. Moreover, postoperative analgesic consumption did not differ significantly between the groups. No major drug-related complication was observed in any study. CONCLUSION:
|
Authors | Ka-Wai Tam, Shin-Yan Chen, Tsai-Wei Huang, Chao-Chun Lin, Chih-Ming Su, Ching-Li Li, Yuan-Soon Ho, Wan-Yu Wang, Chih-Hsiung Wu |
Journal | International journal of surgery (London, England)
(Int J Surg)
Vol. 22
Pg. 79-85
(Oct 2015)
ISSN: 1743-9159 [Electronic] England |
PMID | 26277531
(Publication Type: Journal Article, Meta-Analysis, Review, Systematic Review)
|
Copyright | Copyright © 2015 IJS Publishing Group Limited. Published by Elsevier Ltd. All rights reserved. |
Chemical References |
- Amides
- Anesthetics, Local
- Ropivacaine
- Bupivacaine
|
Topics |
- Amides
(administration & dosage)
- Anesthetics, Local
(administration & dosage)
- Breast Neoplasms
(surgery)
- Bupivacaine
(administration & dosage)
- Female
- Humans
- Mastectomy, Segmental
(adverse effects)
- Pain Management
- Pain Measurement
- Pain, Postoperative
(prevention & control)
- Randomized Controlled Trials as Topic
- Ropivacaine
|